Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Anhorn Medicines Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned across 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution path rather than dispersion across multiple examination groups.
WILLIS, DOUGLAS M is the busiest examiner, with 1 pending matter. Counsel can therefore focus docket review and response planning on one examiner and one art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744538 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | WILLIS, DOUGLAS M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744538 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18744538 | PROTEIN DEGRADATION COMPOUNDS AND METHODS OF USE | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | — | Pending | Jun 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnhorn Medicines Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Douglas M Willis has the most, with 1 of Anhorn Medicines Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.